Skip to main content
. 2022 Sep 21;52(4):1035–1046. doi: 10.1093/ije/dyac176

Table 1.

Characteristics of genotyped male HEALS participants included in analyses of LoY

Randomly selecteda Randomly selected and skin-lesion-freeb Incident skin lesions Prevalent skin lesions
N 778 519 270 361
Age (years)
<30 86 (11.1%) 70 (13.5%) 7 (2.6%) 16 (4.4%)
30–39 282 (36.2%) 204 (39.3%) 55 (20.4%) 92 (25.5%)
40–49 241 (31.0%) 147 (28.3%) 106 (39.3%) 136 (37.7%)
50–59 135 (17.4%) 83 (16.0%) 78 (28.9%) 93 (25.8%)
>59 34 (4.4%) 15 (2.9%) 24 (8.9%) 24 (6.6%)
Body mass index (kg/m2)
<17.5 195 (25.1%) 120 (23.1%) 72 (26.9%) 111 (31.0%)
17.5–18.8 193 (24.8%) 116 (22.4%) 77 (28.7%) 92 (25.7%)
18.9–21.1 195 (25.1%) 141 (27.2%) 62 (23.1%) 94 (26.3%)
>21.1 194 (25.0%) 142 (27.4%) 57 (21.3%) 61 (17.0%)
Cigarette smoking
Never 207 (26.6%) 152 (29.3%) 54 (20.0%) 63 (17.5%)
Former 76 (9.8%) 43 (8.3%) 47 (17.4%) 59 (16.3%)
Current 495 (63.6%) 324 (62.4%) 169 (62.6%) 239 (66.2%)
Education (years)
0 281 (36.1%) 187 (36.0%) 102 (37.8%) 175 (48.5%)
1–5 258 (33.2%) 164 (31.6%) 95 (35.2%) 109 (30.2%)
6–16 239 (30.7%) 168 (32.4%) 73 (27.0%) 77 (21.3%)
Water arsenic (µg/L)
<17 195 (25.1%) 150 (28.9%) 59 (21.9%) 51 (14.1%)
17–71 191 (24.6%) 142 (27.4%) 40 (14.8%) 80 (22.2%)
72–153 196 (25.2%) 132 (25.4%) 64 (23.7%) 98 (27.1%)
>153 196 (25.2%) 95 (18.3%) 107 (39.6%) 132 (36.6%)
Arsenic dose (µg/day)
<37 195 (25.1%) 150 (28.9%) 58 (21.5%) 46 (12.7%)
37–169 194 (24.9%) 151 (29.1%) 46 (17.0%) 73 (20.2%)
170–419 194 (24.9%) 118 (22.7%) 70 (25.9%) 110 (30.5%)
>419 195 (25.1%) 100 (19.3%) 96 (35.6%) 132 (36.6%)
Urinary arsenic (µg/L)
<50 190 (24.8%) 136 (26.4%) 47 (17.9%) 67 (18.7%)
50–103 192 (25.1%) 145 (28.2%) 55 (20.9%) 67 (18.7%)
104–196 191 (25.0%) 129 (25.0%) 73 (27.8%) 114 (31.8%)
>196 192 (25.1%) 105 (20.4%) 88 (33.5%) 111 (30.9%)
a

Frequencies may not sum to the total due to small amounts of missing data.Randomly selected genotyped men may include participants who have or develop skin lesions (see ‘Methods’ section).

b

Randomly selected and skin-lesion-free group were considered our control group and includes randomly selected genotyped men who did not have or develop skin lesions (i.e. free of skin lesions). HEALS, Health Effects of Arsenic Longitudinal Study; LoY, loss of Y chromosome.